an apparent trendP = 0.085
In the ACS sub-group ( Figure 6 ), there is an apparent trend towards a reduction in the gap of prescribing higher potency P2Y 12 inhibitors ( P = 0.085) ( Figure 6A ) with an estimated joinpoint in 2022.
In the ACS sub-group ( Figure 6 ), there is an apparent trend towards a reduction in the gap of prescribing higher potency P2Y 12 inhibitors ( P = 0.085) ( Figure 6A ) with an estimated joinpoint in 2022.